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Background/aim: Off-label drug use (OLDU) is under the control of the Turkish Medicines and Medical Devices Agency (TMMDA) in
Turkey. It was aimed to investigate demographic and medical features of patients with OLDU applications in Turkey.
Materials and methods: A total of 4426 electronic OLDU application records of the TMMDA were evaluated retrospectively.
Information regarding patients’ demographic characteristics, diagnoses, requested drugs, institutions, and specialties of the physicians
were evaluated.
Results: OLDU applications were mostly made by rheumatologists (21.5%) and 95.2% of them were approved by the TMMDA. The
mean age of the patients was 35 years and 54.4% of them were female. Off-label drugs were mostly prescribed for patients aged 18–64
years (62.1%) and were most frequently prescribed by physicians from university medical centers (81.0%). Systemic lupus erythematosus
(10.1%) was the most common diagnosis. Mycophenolate (16.1%) and rituximab (10.1%) were the most frequently prescribed off-label
drugs. There were differences regarding some characteristics of patients and their physicians among most frequently prescribed off-label
drugs (P < 0.05).
Conclusion: It is noteworthy that OLDU applications showed demographical and institutional differences. It is expected that this study
will provide important contributions to physicians working in the relevant area with respect to treatment alternatives of diseases with
treatment challenges.
Key words: Off-label drug use, systemic lupus erythematosus, mycophenolate, rituximab

1. Introduction
Candidate drugs are tested on many issues, particularly
for safety and effectiveness, with detailed preclinical and
clinical trials before getting licensed. Drugs with enough
convincing data in their claimed area are then licensed
by the regulatory authorities for the relevant indication
and population. Due to the various requirements in the
process of drug development, such clinical trials are mostly
performed on “standard people/patients” with certain
features. Therefore, the license information concerning
the appropriate use of the drugs in special populations
such as children, the elderly, and patients with conditions
such as cancer or mental disorders is generally not enough
(1). This situation results in off-label drug use (OLDU)
that covers the use of drugs outside the terms of product
license with regard to age, dosage, route of administration,
indications, and contraindications (2).
OLDU is a common practice throughout the world
with rates reported to be between 18% and 36% in adults
(3–6) and 3%–87% in pediatric patients (7–15). Moreover,
* Correspondence: aakici@marmara.edu.tr

the incidence of OLDU may vary depending on several
factors such as the healthcare facility and the disease
profile (11). Various studies have shown that OLDU is
related to adverse drug reactions (2,16). In addition, it
has been reported that a majority of OLDU applications
possess little or no scientific support (17).
OLDU is legal in many countries (1,2,18), and in
Turkey, it is under the control of the Ministry of Health
(MoH) Turkish Medicines and Medical Devices Agency
(TMMDA). Physicians are required to apply to the
TMMDA on behalf of patients for off-label prescribing. Like
international common definitions (2), OLDU is defined as
“the use of licensed drugs out of the registered indications”
in the “Off-Label Drug Use Guideline” published by the
TMMDA (http://www.titck.gov.tr/Mevzuat/). In the
guideline, it is pointed out that the TMMDA will not allow
OLDU for approved indications and diseases that can be
treated with standard doses of drugs and physicians are
informed about OLDU application procedures and the
forms that they have to fill out. It is also stated that in the
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case of determination of OLDU without permission given
by the TMMDA, legal action will be initiated against the
physician. The TMMDA evaluates OLDU applications
with scientific advisory committees according to the
provisions specified in the guideline. In the case of the
approval of OLDU applications by the TMMDA, the cost
of the licensed drugs will be reimbursed by the Social
Security Institution and unlicensed drugs will be imported
by the Turkish Pharmacists’ Association.
Most of the studies investigating OLDU in the literature
are specific to particular age groups, healthcare facilities,
and indication (3–17). Therefore, there is a need for
pharmacoepidemiological studies assessing OLDU more
thoroughly from a nationwide perspective. The aim of the
present study was to investigate demographic features and
medical conditions of patients who have submitted OLDU
applications to the health authority in Turkey.
2. Materials and methods
This retrospective study was carried out to investigate the
OLDU applications coming from all provinces of Turkey
in 2011. Among these applications, electronic records in
the TMMDA computer database were evaluated. OLDU
applications that resulted in ‘approval’ or ‘rejection’
between 1 January 2011 and 31 December 2011 were
analyzed in the TMMDA database, following approval
by the Ethics Committee of Marmara University Medical
School and permission from the TMMDA.
Parameters such as patients’ demographic
characteristics, diagnoses, requested drugs, institutions,
and specialties of the physicians that submitted the
application (but not identity information of patients or
physicians) were obtained from the OLDU application
records in the TMMDA database. In this study, for ethical
reasons, the patients’ identification information was not
used explicitly, but encoded identification numbers of the
patients were obtained. In order to eliminate the possibility
that an application was assessed more than once for the

same drug for the same patient, encoded identification
numbers were compared one by one with the drugs used.
Duplications were avoided by noting the first encountered
application in the registration system for the patient
relating to the same drug.
Diagnoses were classified according to the
International Classification of Disease (ICD-10). Drugs
were grouped by the anatomic, therapeutic, and chemical
(ATC) classification system. The most common reasons
for rejections in applications of OLDU were identified.
At level 1, ATC classification of the off-label prescribed
drugs by age categories were determined. The results
of applications for OLDU were compared by some
characteristics of patients, their physicians, and the
drugs (status of licensing, administration route, common
subgroups, etc.). Distributions of applications for OLDU
by physicians’ specialties and by months were identified.
The most frequent drugs were analyzed for the five most
frequent diagnoses in OLDU applications. Patients’ age,
sex, and their physicians’ affiliations were compared
among the three most common prescribed off-label drugs.
Statistical analyses were carried out by SPSS 11.5. The
chi-square test was used for the statistical analyses. The
comparisons were considered as statistically significant at
P < 0.05.
3. Results
In this study, 4426 OLDU applications that had been
‘approved’ or ‘rejected’ within the given time period (1
January 2011 to 31 December 2011) were analyzed. Of
these applications, 4214 (95.2%) were approved by the
TMMDA. The most common reason for rejection was
“standard treatment options had not been tried before
the OLDU application was sent” (Table 1). When the
distribution of OLDU applications was analyzed by
calendar month, OLDU applications were highest between
March and September 2011 with a peak in April (13.6%)
and May (13.5%) (Figure 1).

Table 1. Distribution of the reasons for rejection of applications for off-label drug use (OLDU).
The common reasons for rejection

n

%

Standard treatment options had not been tried before the OLDU application was sent.

64

27.4

Patient was not completely evaluated in terms of the other treatment options.

26

11.1

There was no need to take additional approval from the MoH for the use of the drug in the relevant indication.

18

7.7

There were not sufficient scientific data regarding the use of the drug in the relevant diagnosis.

14

6.0

There were not sufficient data on efficacy and safety regarding the use of the drug in the relevant diagnosis.

14

6.0

Patient who had previously received OLDU approval submitted an application for a repeat too early.

11

4.7

Others

87

37.1

Total

234

100.0
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Figure 1. Distribution of applications for off-label drug use (OLDU) by month.

OLDU applications (%)

The mean age of the patients was 34.9 ± 21.6 years
(62.1% of them aged 18–64 years) and more than half of
them were female (54.4%). These patients were followed
by the group under 18 years of age (28.2%).
Off-label drugs were mostly prescribed by physicians
working in university hospitals (UHs), (81.0%), followed
by other healthcare centers (19.0%).

The majority of OLDU applications (96.8%) were
made by internal medicine specialists and 3.2% were
made by physicians from surgical specialties. Among
these specialties, OLDU applications were mostly made
by rheumatologists (21.5%), followed by hematologists
(8.6%) and neurologists (7.9%), (Figure 2). When
physicians’ academic titles were evaluated, it was found

25
20
15
10
5
0

Speciality

Figure 2. Distribution of off-label drug use (OLDU) applications by physician’s specialty.
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that specialist physicians (47.8%) most frequently made
OLDU applications and this was followed by professors
(24.2%) and associate professors (19.2%).
Most of the OLDU applications included one
diagnosis (73.5%); the remaining ones had two or more.
When diagnoses were grouped according to the ICD-10
classification, systemic lupus erythematosus (SLE; ICD10 code: M32; 10.1%) was the most common diagnosis,
followed by other pulmonary heart diseases (PHD; I27;
9.5%), multiple sclerosis (MS; G35; 4.8%), congenital
malformations of cardiac septa (Q21; 4.5%), and
transplanted organ and tissue status (Z94; 4.2%).
When the generic names of the drugs were analyzed,
mycophenolate mofetil (MMF; ATC-5 code: L04AA06;
16.1%) was the most frequently prescribed off-label
drug, followed by rituximab (L01XC02; 10.1%), iloprost
trometamol (B01AC11; 5.7%), immunoglobulin i.v.
(J06BA02; 3.9%), dalfampridine (N07XX07; 3.6%),
infliximab (L04AB02; 3.2%), bosentan (C02KX01;
2.8%), anakinra (L04AC03; 2.8%), sildenafil citrate
(C02KX; 2.3%), and teriparatide (H05AA02; 2.2%). In 13
applications (0.3%), the trade names of the drugs were not
specified.
When the ATC-1 group distributions of the off-label
prescribed drugs were analyzed, “antineoplastic and

immunomodulating drugs” (ATC-1 code: L; 54.3%),
were the most commonly prescribed group. When the
distributions were analyzed by age categories, as under
18 years, 18–64 years, and 65 years or older, the figures
were 34.7%, 64.4%, and 46.5%, respectively. The next most
commonly prescribed groups were “nervous system drugs”
(N; 15.8%) for the patients under 18 and “cardiovascular
system drugs” (C) for both those 18–64 years and 65 years
or older (8.3% and 17.4%, respectively) (Table 2).
Of the ATC-2 group distributions of the off-label
prescribed drugs, “immunosuppressants” (ATC-2 code:
L04; 32.6%) were the most commonly prescribed drugs,
followed by “antineoplastic agents” (L01; 18.2%) and
“antithrombotic agents” (B01; 6.8%).
Almost all OLDU applications (99.1%) consisted of
systemically administered drugs and the oral route (53.9%)
was the most common route of administration. This was
followed by drugs administered intravenously (27.9%)
or subcutaneously (10.3%). One hundred and seven
(2.4%) OLDU applications did not include information
concerning the pharmaceutical form of the drugs; among
the 4319 applications that did, tablets (42.1%) and vials
(32.5%) were the most common pharmaceutical forms.
Of the drugs in the OLDU applications, the majority
of the drugs had been licensed (78.6%) in Turkey. In

Table 2. Distribution of the ATC-1 classification of the off-label prescribed drugs by age categories.
<18 years of age

18–64 years of age

≥65 years of age

Total

n

%

n

%

n

%

n

%

Alimentary tract and metabolism (A)

146

11.7

48

1.7

3

0.7

197

4.5

Blood and blood forming organs (B)

153

12.3

141

5.1

51

11.9

345

7.8

Cardiovascular system (C)

56

4.5

229

8.3

75

17.4

360

8.1

Dermatological (D)

15

1.2

42

1.5

8

1.9

65

1.5

Genitourinary system and sex hormones (G)

20

1.6

11

0.4

2

0.5

33

0.7

Systemic hormonal prep. excluding sex hormones (H)

66

5.3

83

3.0

53

12.3

202

4.6

General antiinfectives for systemic use (J)

65

5.2

163

5.9

22

5.1

250

5.6

Antineoplastic and immunomodulating agents (L)

432

34.7

1771

64.4

200

46.5

2403

54.3

Musculoskeletal system (M)

32

2.6

31

1.1

7

1.6

70

1.6

Nervous system (N)

197

15.8

191

7.0

3

0.7

391

8.8

Antiparasitic products (P)

-

-

2

0.1

2

0.5

4

0.1

Respiratory system (R)

11

0.9

15

0.6

-

-

26

0.6

Sensory organs (S)

-

-

1

0.0

-

-

1

0.0

Various (V)

24

1.9

11

0.4

3

0.7

38

0.9

Others

29

2.3

11

0.4

1

0.2

41

0.9

Total

1246

100.0

2750

100.0

430

100.0

4426

100.0

ATC-1 classification
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comparisons of the approval or rejection status of the
OLDU applications in relation to the licensing status of
the drugs, for physicians’ branches statistically significant
differences were found (P < 0.05). This was due to a
higher rate of rejection (6.0%) for the unlicensed drugs
and applications made by surgeons. Among the top three
diagnoses in OLDU applications, the “other-pulmonary
heart diseases (I27)” indication had more rejections than
SLE and MS. Among the top three prescribed OLDU
drugs, MMF was more highly approved than rituximab
and iloprost trometamol (Table 3).
The top three prescribed drugs (MMF, rituximab, and
iloprost trometamol) were almost 1/3 of all OLDU drugs.
There were statistically significant differences among

these agents based on characteristics of patients’ age and
sex and also their physicians’ affiliations. MMF was most
prescribed to females (71.0%) among the three drugs.
Iloprost trometamol was more prescribed to children
(53.1%) than the other drugs. It was also found that the
drug with the most OLDU applications from surgery
and “nonuniversity healthcare centers” was iloprost
trometamol (Table 4).
For the OLDU applications, the most commonly
declared duration of therapy was in the range of 31–90
days (57.0%).
The top five diagnoses were further examined according
to the ICD-10 classification. The applications were mostly
from UHs for all five common indications (SLE, “other

Table 3. Comparison of the results of applications for off-label drug use (OLDU) based on some characteristics of the drugs, patients
and their physicians.
Approval

n
Licensing status
in Turkey
Route of
administration

Patient’s sex

Patient’s age
group
Physician’s
branch
Physician’s
working place

Top three
diagnoses

Top three drugs

Rejection

%

n

%

n

Licensed (n = 3468)

3314

95.6

154

4.4

Unlicensed (n = 945)

888

94.0

57

6.0

Local (n = 42)

41

97.6

1

2.4

Systemic (n = 4384)

4173

95.2

211

4.8

Male (n = 2017)

1917

95.0

100

5.0

Female (n = 2409)

2297

95.4

112

52.8

Total (n = 4426)

4214

95.2

212

4.8

<18 years (n = 1246)

1195

95.9

51

4.1

18–64 years (n = 2750)

2610

94.9

140

5.1

≥65 years (n = 430)

409

95.1

21

4.9

Internal medicine (n = 4282)

4085

95.4

197

4.6

Surgery (n = 144)

129

89.6

15

10.4

University (n = 3586)

3413

95.2

173

4.8

Others (n = 840)

801

95.4

39

4.6

Systemic lupus erythematosus (M32) (n = 436)

428

98.2

8

1.8

Other pulmonary heart diseases (I27) (n = 230)

201

87.4

29

12.6

Multiple sclerosis (G35) (n = 195)

192

98.5

3

1.5

Total (n = 861)

821

95.3

40

4.7

Mycophenolate mofetil (L04AA06) (n = 607)

606

99.8

1

0.2

Rituximab (L01XC02) (n = 445)

413

92.8

32

7.2

Iloprost trometamol (B01AC11) (n = 254)

229

90.2

25

9.8

Total (n = 1306)

1248

95.6

58

4.4

Statistics
(chi-square)
P < 0.05
P > 0.05

P > 0.05

P > 0.05

P < 0.05

P > 0.05

P < 0.05

P < 0.05
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Table 4. Comparison of the top three off-label drugs based on some characteristics of patients and their physicians.
Mycophenolate mofetil
(L04AA06) (n = 607)

Rituximab
(L01XC02) (n = 445)

Iloprost trometamol
(B01AC11) (n = 254)

%

n

%

n

%

n

Male

176

29.0

211

47.4

100

39.4

Female

431

71.0

234

52.6

154

60.6

<18 years

55

9.1

41

9.2

135

53.1

18–64 years

522

86.0

338

76.0

100

39.4

≥65 years

30

4.9

66

14.8

19

7.5

Internal medicine

605

99.7

441

99.1

229

90.2

Surgery

2

0.3

4

0.9

25

9.8

University

519

85.5

382

85.8

147

57.9

Other healthcare center

88

14.5

63

14.2

107

42.1

n

Patient’s sex

Patient’s age group

Physician’s branch
Physician’s working
place

PHD”, MS, “congenital malformations of cardiac septa”,
and “transplanted organ and tissue status” at 91.7%, 66.1%,
75.6%, 56.7%, and 75.0%, respectively).
Of the 445 OLDU applications with SLE diagnosis, 438
(98.4%) applications were approved. Most of the patients
(86.1%) were female and they were mostly between 18 and
64 years old (89.7%). The most frequent applicants were
rheumatologists (77.1%). The majority of the off-label
drugs prescribed for SLE were licensed in Turkey (98.9%).
MMF (78.9%) was the most frequently prescribed off-label
drug for SLE (Table 5).
Of the 419 OLDU applications with “other PHD”
diagnosis, 390 (93.1%) applications were approved. Most
of the patients (59.7%) were female and they were mostly
under 18 (40.6%). Most of the applicants were pediatric
cardiologists (42.7%). The majority of the off-label drugs
prescribed for other PHD were licensed in Turkey (98.6%).
Iloprost trometamol (59.9%) was the most frequently
prescribed off-label drug for other PHD diagnoses (Table
5).
Of the 213 OLDU applications with MS diagnosis, 210
(98.6%) applications were approved. Most of the patients
(67.6%) were female and they were mostly between 18
and 64 years old (92.5%). The most frequent applicants
were neurologists (97.2%). The majority (81.2%) of
off-label drugs prescribed for MS were unlicensed in
Turkey. Dalfampridine (75.1%), was the most frequently
prescribed off-label drug for MS (Table 5).
Of the 201 OLDU applications with a diagnosis of
“congenital malformations of cardiac septa”, 199 (99.0%)
applications were approved. Most of the patients (59.2%)
were female and they were mostly under 18 years (59.7%).
Most of the applicants were pediatric cardiologists (63.7%).

1234

Statistics
(chi-square)
P < 0.05

P < 0.05

P < 0.05
P < 0.05

The majority (99.0%) of the off-label drugs prescribed for
this diagnosis were licensed in Turkey. Iloprost trometamol
(73.6%) was the most frequently prescribed off-label drug
(Table 5).
Of the 184 OLDU applications with “transplanted
organ and tissue status” diagnosis, 172 (93.5%) applications
were approved. Most of the patients (60.3%) were male
and they were mostly between 18 and 64 years old (73.9%).
The most frequent applicants were nephrologists (25.0%).
The majority of the off-label drugs prescribed for this
diagnosis were found to be licensed in Turkey (92.8%).
MMF (16.8%) was the most frequently prescribed off-label
drug (Table 5).
4. Discussion
Evaluation of OLDU can provide insights and assistance
for the healthcare providers who are making the
regulations and in addition can raise the awareness of
physicians about disorders, their treatment challenges, and
the potential treatment alternatives. We have conducted
a detailed analysis of the OLDU applications without
any restrictions regarding age group, healthcare facility,
or diagnosis. Except for earlier studies that evaluated
OLDU in the specific fields of neonatology, oncology,
and endocrinology, this is the first study to investigate the
extent of OLDU at a national level in Turkey (15,19,20).
The present study showed that the most common reason
for the rejection of OLDU applications was “standard
treatment options had not been tried before the OLDU
application was sent” (Table 1). Similar reasons were also
reported in a recent study that assessed endocrinological
OLDU applications in Turkey (20). In addition, the
proportion of rejection of OLDU application was higher

ÖZDAMAR et al. / Turk J Med Sci
Table 5. Distribution of the most frequent drugs prescribed for the five most frequent diagnoses in off-label drug use (OLDU)
applications.
Rank

1

2

3

4

5

Diagnoses (ICD- 10)

Systemic lupus erythematosus (M32)

Other pulmonary heart diseases (I27)

Multiple sclerosis (G35)

Congenital malformations of cardiac septa
(Q21)

Transplanted organ and tissue status (Z94)

Drugs (ATC code)

Applications, n (%)

Mycophenolate mofetil (L04AA06)

351 (78.9)

Rituximab (L01XC02)

69 (15.5)

Immunoglobulin i.v. (J06BA02)

11 (2.5)

Others

14 (3.1)

Total

445 (100.0)

Iloprost trometamol (B01AC11)

251 (59.9)

Sildenafil (C02KX)

92 (22.0)

Bosentan (C02KX01)

65 (15.5)

Others

11 (2.6)

Total

419 (100.0)

Dalfampridine (N07XX07)

160 (75.1)

Fingolimod (L04AA27)

18 (8.5)

Natalizumab (L04AA23)

12 (5.6)

Others

23 (10.8)

Total

213 (100.0)

Iloprost trometamol (B01AC11)

148 (73.6)

Sildenafil (C02KX)

41 (20.4)

Bosentan (C02KX01)

10 (5.0)

Others

2 (1.0)

Total

201 (100.0)

Mycophenolate mofetil (L04AA06)

31 (16.8)

Sirolimus (L04AA10)

26 (14.1)

Rituximab (L01XC02)

24 (13.0)

Others

103 (56.1)

Total

184 (100.0)

in surgery than internal medicine (Table 3).These findings
point out the need for physicians’ specific attention and
focus group educational programs regarding potential
causes of refusal of OLDU applications.
“Antineoplastic and immunomodulating drugs”
(54.3%) were found as the most common off-label drugs
in all age groups (Table 2). On the other hand, oncology
and pediatric oncology were ranked as 6th and 18th in the
distribution of OLDU applications by physicians’ specialties
(Figure 2). These findings showed that “antineoplastic and
immunomodulating drugs” were mostly preferred by the
nononcologist specialists in OLDU applications.

Off-label drug use applications were found to be
increased during the spring and summer (Figure 1). These
seasonal variations may be related to the increase in the
activities of common diagnoses found in this study, such
as SLE and MS, which are characterized by attacks and
remissions (21,22).
Off-label prescription with respect to age groups is a
common practice worldwide, particularly for children
and the elderly, who are commonly excluded from the
clinical trials necessary to obtain approval by regulatory
authorities. Notably, recent studies that have investigated
OLDU mainly focused on the pediatric age group (7–15).
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On the other hand, a limited number of studies have been
published regarding OLDU in the elderly. A study of
elderly patients admitted to three wards of a hospital in
the United Kingdom found that 84% of the hospitalized
elderly patients were prescribed drugs in an off-label or
unlicensed way (23). Another study investigating the
off-label use of second-generation antipsychotic agents
among elderly nursing home residents in the United States
reported that 86% of these agents prescribed to the elderly
were for off-label indications (24). In our study, off-label
drugs were mostly prescribed for patients aged 18 to 64
years (62.1%), followed by the pediatric age group (28.2%).
Contrary to the studies in the literature, the elderly
constituted a small proportion (9.7%). It is an interesting
finding that although drug use is common in the elderly
(25,26), we found a lower OLDU rate for this age group
in our study. On the other hand, the overbalance of offlabel use in young adults and children and the female
predominance in the applications could be associated with
the nature of the most common diagnoses found in this
study, such as SLE, MS, and other PHD (27–29).
UHs are tertiary healthcare centers that have the
healthcare service capacity to treat more serious illnesses
and embody specific subspecialties. In concordance with
this, we found that OLDU applications were most
frequently from UHs (81.0%).
When OLDU applications are analyzed according to
the diagnoses, applications with the most common five
diagnoses, respectively SLE, other PHD, MS, congenital
malformations of cardiac septa, and transplanted organ
and tissue status, constituted one-third of all applications
(33.1%). When the distributions of the first three off-label
drugs prescribed for the five most frequent diagnoses
were evaluated, it was found that MMF was in first place
for SLE and transplanted organ and tissue status, iloprost
trometamol for other PHD and congenital malformations
of cardiac septa, and dalfampridine for MS (Table 5).
SLE is an autoimmune disease with considerable
morbidity and mortality. First-line therapies for patients
with SLE consist of hydroxychloroquine, corticosteroids,
and nonsteroidal antiinflammatory drugs (30). Even
though the pathogenesis of SLE is not fully understood,
current experimental evidence suggests that B
lymphocytes play an important role in the pathogenesis
by producing autoantibodies (31), which supports the
potential usefulness of B cell depletion therapy for SLE.
Rituximab is a chimeric monoclonal antibody that targets
the human CD20 antigen, which is found on the surface
of B lymphocytes. Rituximab has been increasingly used
off-label for the treatment of certain conditions such as
autoimmune diseases, dermatological conditions, and
solid organ transplantations (32–34).
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Following the first report in 2002 (35), a large number of
studies have been carried out on the off-label use of rituximab
in patients with SLE. In a study that systematically examined
the case reports and observational studies related to the
use of rituximab between 2002 and 2007, it was reported
that a total of 188 patients were treated with rituximab and
91% of them showed significant improvement of one or
more systemic symptoms of SLE (36). Although rituximab
has given successful results in the treatment of severe SLE
symptoms in case series, two randomized placebo-controlled
trials could not show a significant benefit from rituximab in
patients with SLE and lupus nephritis (37,38). In Australia,
a retrospective study analyzing the off-label use of rituximab
in a tertiary care hospital reported that favorable outcomes
were obtained in the prevention and treatment of renal
transplant rejection and SLE nephritis (39). We found in our
study that rituximab is among one of the most commonly
prescribed off-label drugs for SLE and transplantation
indications in line with the international literature reporting
increased off-label use of rituximab.
In this study, MMF was the most frequently preferred
drug both for SLE and transplantation indications (Table
5). MMF is an immunosuppressive drug that is approved
for the prevention of allograft rejection after kidney, liver,
and heart transplantation. MMF shows its activity by
suppressing the B and T lymphocyte proliferation and
the production of autoantibodies, and it gives successful
results in autoimmune diseases such as SLE, RA, and
systemic vasculitis (40). On the other hand, there are not
enough data concerning the use of MMF for nonrenal
manifestations (hematologic, pulmonary, cutaneous,
neuropsychiatric, myocardial, etc.) in SLE patients (41).
The diagnosis of other PHD involves primary and
secondary pulmonary hypertension (PHT), which are
characterized by increased pressure in the pulmonary
circulatory system (42). Inhaled iloprost trometamol is a
prostacyclin analog that is approved for the treatment of
primary (idiopathic or familial) PHT and PHT associated
with scleroderma. Particularly in children, the absence of
an approved therapy for PHT results in off-label use of
inhaled iloprost in this age group (43). In line with this, we
found that the patients with the diagnosis of other PHD
were mostly under the age of 18 (Tables 4 and 5).
MS is a neurological disorder that affects the optic
nerves and spinal cord and is characterized by axonal
damage, demyelization, and inflammation. Dalfampridine,
a potassium channel blocker, was approved by the FDA
in order to improve walking in patients with MS (44).
However, dalfampridine is included in the scope of OLDU,
because it is unlicensed in Turkey, as seen in this study.
The OLDU application process can be influenced by
many factors, such as drug- and disease-centered, patientrelated, and the physician’s preferences. Indeed, this study
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showed that the approval proportions were higher for
licensed drugs, drugs requested by internal medicine,
and drugs for the treatment of MS and SLE (Table 3).
Therefore, before submitting applications to the OLDU
process, physicians should be aware of the OLDU status of
drugs that are especially related to their specialty.
There are some limitations of our study that need to
be mentioned. We could not carry out a comprehensive
evaluation regarding the underlying secondary diseases
of patients. Furthermore, we could not assess the adverse
reactions due to OLDU.
In conclusion, the present study has made a
comprehensive evaluation of the OLDU applications
that were made to the TMMDA in 2011 and has

presented important findings about OLDU. OLDU
showed institutional, seasonal, and some demographical
differences. It is expected that this study will provide
important contributions to physicians working in the
relevant area with respect to treatment alternatives of
diseases with treatment challenges.
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